Phaseline

Targets › CDK2

CDK2 (Cyclin-dependent kinase 2): drug programs, companies and trials

13 programs from 11 companies in 18 trials: 11 Phase 1, 5 Phase 2, 2 Phase 3; Oncology; next expected readout Dec 2026.

Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CABLES1, CTNNB1, CDK2AP2, ERCC6, NBN, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, SUV39H1, EZH2. (UniProt, P24941)

Open in Phaseline: the race on CDK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chia Tai Tianqing Pharmaceutical GroupTQB3616 capsule
CDK2/4/6 inhibitor
CDK2, CDK4, CDK6Phase 3HR-positive, HER2-negative Breast Neoplasms; Breast Cancer; Metastatic Breast CancerDec 2026
National Cancer Institute (NCI)Dinaciclib
Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 5 inhibitor
CDK1, CDK2, CDK5, CDK9Phase 2Acral Lentiginous Melanoma; Advanced Malignant Solid NeoplasmMar 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineCulmerciclib
CDK2/4/6 inhibitor
CDK2, CDK4, CDK6Phase 2HR+/HER2- Early Breast CancerMay 2028
Fudan UniversityCulmerciclib
CDK2/4/6 inhibitor
CDK2, CDK4, CDK6Phase 2Breast CancerJun 2028
Sun Yat-sen UniversityCulmerciclib
CDK2/4/6 inhibitor
CDK2, CDK4, CDK6Phase 2Breast CancerDec 2028
AstraZenecaAZD8421
CDK2 inhibitor
CDK2Phase 1ER+ HER2- Advanced Breast CancerJun 2027
Incyclix BioINX-315
CDK2 inhibitor
CDK2Phase 1Breast CancerJul 2027
NiKang TherapeuticsNKT5097
CDK2/CDK4 dual degrader
CDK2, CDK4Phase 1HR+ Breast CancerJul 2027
BeiGeneBG-68501
Cyclin-dependent kinase-2 inhibitor
CDK2Phase 1Breast CancerAug 2027
Eilean TherapeuticsZE94-0605
Selective cyclin-dependent kinase 2 (CDK2) inhibitor
CDK2Phase 1Advanced Solid Tumor CancerJan 2028
Avenzo TherapeuticsAVZO-021
CDK2 inhibitor
CDK2Phase 1Advanced Solid Tumor; HR+/HER2- Breast CancerJan 2028
National Cancer Institute (NCI)Zotiraciclib
Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor
CDK1, CDK2, CDK7, CDK9, FLT3Phase 1Brain TumorAug 2028
NiKang TherapeuticsNKT3964
CDK2 Degrader
CDK2Phase 1Solid TumorJan 2029

Conditions

Breast Cancer (6) Brain Tumor (1) HR+/HER2- Early Breast Cancer (1) Advanced Solid Tumor (1) HR+/HER2- Breast Cancer (1) HR-positive, HER2-negative Breast Neoplasms (1) Metastatic Breast Cancer (1) Solid Tumor (1) ER+ HER2- Advanced Breast Cancer (1) Acral Lentiginous Melanoma (1) Advanced Malignant Solid Neoplasm (1) Advanced Solid Tumor Cancer (1)

Modalities

small molecule (12), mixed (1)

Companies

National Cancer Institute (NCI) (2) NiKang Therapeutics (2) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Avenzo Therapeutics (1) Chia Tai Tianqing Pharmaceutical Group (1) BeiGene (1) Sun Yat-sen University (1) AstraZeneca (1) Eilean Therapeutics (1) Fudan University (1) Incyclix Bio (1)

Related targets

CDK4 (5) CDK6 (4) CDK1 (2) CDK9 (2) CDK7 (1) FLT3 (1) CDK5 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.